Literature DB >> 27522138

Invasive pneumococcal disease in Australia, 2011 and 2012.

Cindy Toms1, Rachel de Kluyver1.   

Abstract

In Australia, there were 1,883 cases (8.3 per 100,000 population) of invasive pneumococcal disease (IPD) notified to the National Notifiable Diseases Surveillance System (NNDSS) in 2011 and 1,823 cases (8.0 per 100,000) in 2012. The overall rate of IPD in Indigenous Australians was 9 times the rate of IPD in non-Indigenous Australians in 2011 and 7 times in 2012. Following the July 2011 introduction of the 13-valent pneumococcal conjugate vaccine (13vPCV) to the National Immunisation Program, rates of IPD in children aged less than 5 years decreased from 19.5 per 100,000 in 2011 to 12.6 per 100,000 in 2012. In Indigenous adults aged 50 years or over the rates of IPD caused by serotypes included in the 23-valent pneumococcal polysaccharide vaccine (23vPPV) continued to increase in both 2011 (47.2 per 100,000) and 2012 (51.2 per 100,000). The rates of IPD in non-Indigenous adults aged 65 years or over caused by serotypes included in the 23vPPV also increased in 2011 (10.1 per 100,000) and 2012 (11.2 per 100,000). There were 134 deaths attributable to IPD in 2011 and 126 in 2012, although it should be noted that deaths may be under-reported. The number of invasive pneumococcal isolates with reduced penicillin susceptibility remained low and reduced susceptibility to ceftriaxone/cefotaxime continued to be rare.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27522138

Source DB:  PubMed          Journal:  Commun Dis Intell Q Rep        ISSN: 1447-4514


  4 in total

1.  Pneumococcal vaccination uptake among patients aged 65 years or over in Australian general practice.

Authors:  Oliver Frank; Carla De Oliveira Bernardo; David Alejandro González-Chica; Kristine Macartney; Robert Menzies; Nigel Stocks
Journal:  Hum Vaccin Immunother       Date:  2020-01-17       Impact factor: 3.452

2.  Efficacy of oral amoxicillin-clavulanate or azithromycin for non-severe respiratory exacerbations in children with bronchiectasis (BEST-1): a multicentre, three-arm, double-blind, randomised placebo-controlled trial.

Authors:  Vikas Goyal; Keith Grimwood; Robert S Ware; Catherine A Byrnes; Peter S Morris; I Brent Masters; Gabrielle B McCallum; Michael J Binks; Heidi Smith-Vaughan; Kerry-Ann F O'Grady; Anita Champion; Helen M Buntain; André Schultz; Mark Chatfield; Paul J Torzillo; Anne B Chang
Journal:  Lancet Respir Med       Date:  2019-08-16       Impact factor: 30.700

3.  Effectiveness of 7-Valent Pneumococcal Conjugate Vaccine Against Invasive Pneumococcal Disease in Medically At-Risk Children in Australia: A Record Linkage Study.

Authors:  Alamgir Kabir; Anthony T Newall; Deborah Randall; Hannah C Moore; Sanjay Jayasinghe; Parveen Fathima; Bette Liu; Peter McIntyre; Heather F Gidding
Journal:  J Pediatric Infect Dis Soc       Date:  2022-09-29       Impact factor: 5.235

4.  Associations between ethnicity, social contact, and pneumococcal carriage three years post-PCV10 in Fiji.

Authors:  Eleanor F G Neal; Stefan Flasche; Cattram D Nguyen; F Tupou Ratu; Eileen M Dunne; Lanieta Koyamaibole; Rita Reyburn; Eric Rafai; Mike Kama; Belinda D Ortika; Laura K Boelsen; Joseph Kado; Lisi Tikoduadua; Rachel Devi; Evelyn Tuivaga; Catherine Satzke; E Kim Mulholland; W John Edmunds; Fiona M Russell
Journal:  Vaccine       Date:  2019-10-23       Impact factor: 3.641

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.